SAKAR2026-04-012026-06-30SAKAR2026-04-012026-06-30in-capmkt:OtherExpenses1MemberSAKAR2026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares000000SAKARNOTLISTEDINE732S01012Sakar Healthcare LimitedMain BoardEquity2026-04-012027-03-312026-07-242026-07-20INRLakhsQuarterlyFirst quarterSingle segmentPharmaceuticals2026-07-2411:30:002026-07-2412:00:00Not applicablefalsefalseAs on date note applicable2026-04-012026-06-30UnauditedStandalone729725000154390007451640004003520000-5453000011455100016697000654240005686300059935700014580700001458070003934200036160004295800001028490000000102849000-267000102582000222499000104.624.62004.624.621 The Company is operating only in one segment i.e. Manufacturing of Pharmaceutical Products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. Hence segment reporting is not given. <br /> <br /> 2 The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. <br /> <br /> 3 The Company has a wholly owned subsidiary vis. M/s. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/ associate. <br /> <br /> 4 Provision for taxation/deferred taxation, if any, will be made at the year end. <br /> <br /> 5 Figures, wherever required, are regrouped / rearranged. <br /> <br /> 6 The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 24th July 2026 <br /> <br /> 7 The figures for quarter ended on 31st March, 2026 are the balancing figures between the audited figures in respect of the full financial year ended on 31st March, 2026 and the year to date figures upto the third quarter of the financial year. <br /> <br /> Other Expenses56863000Re-measurement gains/(losses) on defined benefit plans-370000-370000-1030000-267000